Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CRHBP | P24387 | 1/20 | 1.00 |
| ▸ | CRHR2 | Q13324 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.80 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.63 |
| ▸ | GRN | P28799 | 1/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.55 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.55 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899837 | 0.92 | NPSR1 (0.85) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1902223 | 0.88 | NPSR1 (0.78) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1899487 | 0.86 | GAA (0.76) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1896635 | 0.84 | NPSR1 (0.72) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1898164 | 0.82 | NPSR1 (0.89) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1900130 | 0.81 | GAA (0.69) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL146787 | 0.81 | NPSR1 (0.74) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1899685 | 0.80 | NPSR1 (0.85) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1902248 | 0.80 | NPSR1 (0.71) | NPSR1MAPTCRHBPCRHR2GAA | |
| SCHEMBL1905801 | 0.80 | NPSR1 (0.77) | NPSR1MAPTCRHBPCRHR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| EP-1252156-B1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UCL BUSINESS PLC (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | NPSR1 1816/4885MAPT 1326/4885CRHBP 4564/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | NPSR1 1770/4885MAPT 1289/4885CRHBP 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.